Siri A Mauseth1, Svetlana Skurtveit, Olav Spigset. 1. Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
OBJECTIVE: To investigate the pattern of use of anticholinergic drugs for overactive bladder among women in Norway with regard to persistence, adherence and switch rates. DESIGN: Observational study. SETTING AND SAMPLE: Data from the Norwegian Prescription Database on prescriptions for tolterodine, solifenacin, darifenacin and fesoterodine filled in Norwegian pharmacies from 1 January 2004 to 31 December 2010. METHODS AND MAIN OUTCOME MEASURES: Data from the database were analysed at an individual level, and drug persistence, discontinuation rates and switch rates during a follow-up period of 365 days after the first prescription were calculated. RESULTS: Overall 1-year persistence for new users was 38.0%. Within the same period, a total of 10.3% switched from the index drug to another drug in the same group, whereas 51.7% discontinued without switching. Users of solifenacin and tolterodine were somewhat more persistent than users of darifenacin and fesoterodine. Persistence was lowest (20.9%) in the age group 18-39 years, increased with age and was highest in the age groups 70-79 years and 80 years and above (43.5 and 43.3%, respectively). In total, 31.9% filled only one prescription of the drug and, of these, only one of four women switched to another drug. The proportion who were adherent during treatment was 60.4%. CONCLUSIONS: The discontinuation rate for anticholinergic drugs for overactive bladder in women is high. The reasons why patients stop using them remain obscure but could be related both to a limited clinical effect and an unacceptable adverse effect burden.
OBJECTIVE: To investigate the pattern of use of anticholinergic drugs for overactive bladder among women in Norway with regard to persistence, adherence and switch rates. DESIGN: Observational study. SETTING AND SAMPLE: Data from the Norwegian Prescription Database on prescriptions for tolterodine, solifenacin, darifenacin and fesoterodine filled in Norwegian pharmacies from 1 January 2004 to 31 December 2010. METHODS AND MAIN OUTCOME MEASURES: Data from the database were analysed at an individual level, and drug persistence, discontinuation rates and switch rates during a follow-up period of 365 days after the first prescription were calculated. RESULTS: Overall 1-year persistence for new users was 38.0%. Within the same period, a total of 10.3% switched from the index drug to another drug in the same group, whereas 51.7% discontinued without switching. Users of solifenacin and tolterodine were somewhat more persistent than users of darifenacin and fesoterodine. Persistence was lowest (20.9%) in the age group 18-39 years, increased with age and was highest in the age groups 70-79 years and 80 years and above (43.5 and 43.3%, respectively). In total, 31.9% filled only one prescription of the drug and, of these, only one of four women switched to another drug. The proportion who were adherent during treatment was 60.4%. CONCLUSIONS: The discontinuation rate for anticholinergic drugs for overactive bladder in women is high. The reasons why patients stop using them remain obscure but could be related both to a limited clinical effect and an unacceptable adverse effect burden.
Authors: Anthony G Visco; Linda Brubaker; J Eric Jelovsek; Tracey S Wilson; Peggy Norton; Halina M Zyczynski; Cathie Spino; Larry Sirls; John N Nguyen; David D Rahn; Susie F Meikle; Tracy L Nolen Journal: Female Pelvic Med Reconstr Surg Date: 2016 Jan-Feb Impact factor: 2.091
Authors: Scott Martin Vouri; Mario Schootman; Seth A Strope; Hong Xian; Margaret A Olsen Journal: Arch Gerontol Geriatr Date: 2018-09-22 Impact factor: 3.250
Authors: Christopher J D Wallis; Colin Lundeen; Nicole Golda; Hilary Brotherhood; Peter Pommerville; Lesley Carr Journal: Can Urol Assoc J Date: 2016-08 Impact factor: 1.862
Authors: Jan Krhut; Alois Martan; Roman Zachoval; Tomas Hanus; Lukas Horcicka; Kamil Svabík; Peter Zvara Journal: Int Urol Nephrol Date: 2018-01-10 Impact factor: 2.370